A minimal consortium capable of inducing CD8 T cells was administered with checkpoint inhibitor antibodies to tumor-bearing mice to assess anti-cancer activity and the level of accumulation of tumor infiltrating lymphocytes. The gene discussed is CD8A; the disease is neoplasm.